Skip to content

Safety and long-term efficacy of radiofrequency ablation in the treatment of hepatocellular carcinoma patients with chronic diseases: a single-center retrospective clinical study

Safety and long-term efficacy of radiofrequency ablation in the treatment of hepatocellular carcinoma patients with chronic diseases: a single-center retrospective clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102593
Enrollment
Unknown
Registered
2025-05-16
Start date
2025-05-31
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hepatocellular carcinoma

Interventions

Observation group:None

Sponsors

The First Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Age over 18; 2.The diagnosis of primary hepatocellular carcinoma was based on pathological examination or the diagnostic criteria of American AASLD liver cancer diagnosis and treatment guidelines and Chinese liver cancer diagnosis and treatment guidelines ( 2022 edition ). 3.The diameter of single tumor <= 5cm, the number of multiple tumors <= 3 and the maximum tumor diameter <= 3cm. 4.Preoperative diagnosis of other chronic medical conditions (categories in the Charlson comorbidity index list); 5.Patients with hepatocellular carcinoma who underwent ultrasound-guided radiofrequency ablation of hepatocellular carcinoma;

Exclusion criteria

Exclusion criteria: 1.The pathological results were other types of tumors, such as cholangiocarcinoma, metastatic liver cancer, adenocarcinoma, etc. 2.Palliative treatment for patients with primary liver cancer. 3.TACE was performed within 3 months before operation. 4.Medical records or telephone follow-up time less than 1 year and no death outcome within 1year. 5.Tumor metastasis to other organs.

Design outcomes

Primary

MeasureTime frame
Overall survival;

Secondary

MeasureTime frame
Postoperative Complications;

Countries

China

Contacts

Public ContactMa Kuansheng

The First Affiliated Hospital of Army Medical University

makuansheng@vip.sina.com+86 15213249505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026